Euglycemic DKA ID ’ d in T2DM Patients With COVID - 19
Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS - CoV - 2 infection (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 5, 2021 Category: Respiratory Medicine Tags: Endocrinology, Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nephrology, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news
Top Cardiology Trials of 2020 in Review Top Cardiology Trials of 2020 in Review
The annual tradition continues as did cardiology research despite a pandemic. Trials on fish oils, statins, SGLT2 inhibitors, and antiplatelets are among the selections of Drs Harrington and Gibson.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 15, 2020 Category: Cardiology Tags: Cardiology Expert Interview Source Type: news
New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD
' We would not recommend initiating treatment with SGLT2 inhibitor in eGFR (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Canagliflozin Beneficial Even for Advanced Kidney Disease
MONDAY, Nov. 30, 2020 -- Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the rate of kidney disease progression among participants with an estimated glomerular filtration rate (eGRF)<30 mL/min/1.73 m2,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2020 Category: Pharmaceuticals Source Type: news
Regression of LV Hypertrophy With SGLT2 Inhibitors Regression of LV Hypertrophy With SGLT2 Inhibitors
A new study investigates the potential beneficial effects of SGLT2 inhibitors on left ventricular hypertrophy in patients with T2DM. What might be the mechanisms underlying these effects?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
New diabetes medication reduced heart event risk in those with diabetes and kidney disease
(American Heart Association) Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.Researchers say the results of this randomized clinical trial provide evidence that SGLT2 inhibitors should be part of the standard of care for people with Type 2 diabetes and chronic kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news
SCORED and SOLOIST Trials Add to Evidence for Treating Diabetes with SGLT2 Inhibitors
• SCORED trial of patients with diabetes and chronic kidney disease is first trial of an SGLT2 inhibitor to show benefit across the full range of albuminuria • SOLOIST is the first trial to show an SGLT2 inhibitor is safe to start in patients hospit (Source: BWH News)
Source: BWH News - November 16, 2020 Category: Hospital Management Source Type: news
SCORED and SOLOIST trials add to evidence for treating diabetes with SGLT2 inhibitors
(Brigham and Women's Hospital) In these two paired trials, teams of investigators led by Brigham cardiologist Deepak L. Bhatt, MD, MPH, evaluated sotagliflozin, a drug that inhibits SGLT2 and SGLT1. Results of the trials are both published in The New England Journal of Medicine and presented by Bhatt simultaneously at the Late-Breaking Clinical Trial Sessions of the American Heart Association Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2020 Category: International Medicine & Public Health Source Type: news
Empagliflozin Favorably Reshaped LVs in HFrEF Patients Empagliflozin Favorably Reshaped LVs in HFrEF Patients
Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of patients with heart failure with reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Adverse Events of High- vs Low-Dose SGLT2 Inhibitors in T2D Adverse Events of High- vs Low-Dose SGLT2 Inhibitors in T2D
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes, but they are not without side effects. Are the adverse events associated with these agents dose-related?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups
The benefits of SGLT2 inhibitors are seen in patients with heart failure and in those with chronic kidney disease, data from two pivotal trials, EMPEROR-Reduced and DAPA-CKD, show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
ESC 2020 Highlights: Drugs Old and New ESC 2020 Highlights: Drugs Old and New
Top trials from the virtual ESC 2020 featured old drugs such as aspirin and colchicine as well as the new SGLT2 inhibitors.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 12, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news
October 9 2020 This Week in Cardiology October 9 2020 This Week in Cardiology
COVID-19, scientific philosophy, left main coronary artery disease, empagliflozin and the SGLT2 inhibitors are the topics discussed by John Mandrola, MD in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 9, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan Empagliflozin's HFrEF Benefit Steady With Sacubitril/Valsartan
The SGLT2 inhibitor empagliflozin works just as well when added on top of a second major agent used to treat patients with heart failure and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression, the AHA says.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 28, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
